BACKGROUND: Asthma is a known risk factor for acute ozone-associated respiratory disease. Ozone causes an immediate decrease in lung function and increased airway inflammation. The role of atopy and asthma in modulation of ozone-induced inflammation has not been determined. OBJECTIVE: We sought to determine whether atopic status modulates ozone response phenotypes in human subjects. METHODS: Fifty volunteers (25 healthy volunteers, 14 atopic nonasthmatic subjects, and 11 atopic asthmatic subjects not requiring maintenance therapy) underwent a 0.4-ppm ozone exposure protocol. Ozone response was determined based on changes in lung function and induced sputum composition, including airway inflammatory cell concentration, cell-surface markers, and cytokine and hyaluronic acid concentrations. RESULTS: All cohorts experienced similar decreases in lung function after ozone. Atopic and atopic asthmatic subjects had increased sputum neutrophil numbers and IL-8 levels after ozone exposure; values did not significantly change in healthy volunteers. After ozone exposure, atopic asthmatic subjects had significantly increased sputum IL-6 and IL-1beta levels and airway macrophage Toll-like receptor 4, Fc(epsilon)RI, and CD23 expression; values in healthy volunteers and atopic nonasthmatic subjects showed no significant change. Atopic asthmatic subjects had significantly decreased IL-10 levels at baseline compared with healthy volunteers; IL-10 levels did not significantly change in any group with ozone. All groups had similar levels of hyaluronic acid at baseline, with increased levels after ozone exposure in atopic and atopic asthmatic subjects. CONCLUSION: Atopic asthmatic subjects have increased airway inflammatory responses to ozone. Increased Toll-like receptor 4 expression suggests a potential pathway through which ozone generates the inflammatory response in allergic asthmatic subjects but not in atopic subjects without asthma. Published by Mosby, Inc.
BACKGROUND:Asthma is a known risk factor for acute ozone-associated respiratory disease. Ozone causes an immediate decrease in lung function and increased airway inflammation. The role of atopy and asthma in modulation of ozone-induced inflammation has not been determined. OBJECTIVE: We sought to determine whether atopic status modulates ozone response phenotypes in human subjects. METHODS: Fifty volunteers (25 healthy volunteers, 14 atopic nonasthmatic subjects, and 11 atopic asthmatic subjects not requiring maintenance therapy) underwent a 0.4-ppm ozone exposure protocol. Ozone response was determined based on changes in lung function and induced sputum composition, including airway inflammatory cell concentration, cell-surface markers, and cytokine and hyaluronic acid concentrations. RESULTS: All cohorts experienced similar decreases in lung function after ozone. Atopic and atopic asthmatic subjects had increased sputum neutrophil numbers and IL-8 levels after ozone exposure; values did not significantly change in healthy volunteers. After ozone exposure, atopic asthmatic subjects had significantly increased sputum IL-6 and IL-1beta levels and airway macrophage Toll-like receptor 4, Fc(epsilon)RI, and CD23 expression; values in healthy volunteers and atopic nonasthmatic subjects showed no significant change. Atopic asthmatic subjects had significantly decreased IL-10 levels at baseline compared with healthy volunteers; IL-10 levels did not significantly change in any group with ozone. All groups had similar levels of hyaluronic acid at baseline, with increased levels after ozone exposure in atopic and atopic asthmatic subjects. CONCLUSION: Atopic asthmatic subjects have increased airway inflammatory responses to ozone. Increased Toll-like receptor 4 expression suggests a potential pathway through which ozone generates the inflammatory response in allergic asthmatic subjects but not in atopic subjects without asthma. Published by Mosby, Inc.
Authors: Neil E Alexis; John C Lay; Kirby Zeman; William E Bennett; David B Peden; Joleen M Soukup; Robert B Devlin; Susanne Becker Journal: J Allergy Clin Immunol Date: 2006-04-27 Impact factor: 10.793
Authors: Shama Ahmad; Aftab Ahmad; Glen McConville; Barbara K Schneider; Corrie B Allen; Rizwan Manzer; Robert J Mason; Carl W White Journal: Free Radic Biol Med Date: 2005-03-28 Impact factor: 7.376
Authors: Dianhua Jiang; Jiurong Liang; Juan Fan; Shuang Yu; Suping Chen; Yi Luo; Glenn D Prestwich; Marcella M Mascarenhas; Hari G Garg; Deborah A Quinn; Robert J Homer; Daniel R Goldstein; Richard Bucala; Patty J Lee; Ruslan Medzhitov; Paul W Noble Journal: Nat Med Date: 2005-10-23 Impact factor: 53.440
Authors: Jonathan A Bernstein; Neil Alexis; Charles Barnes; I Leonard Bernstein; Jonathan A Bernstein; Andre Nel; David Peden; David Diaz-Sanchez; Susan M Tarlo; P Brock Williams Journal: J Allergy Clin Immunol Date: 2004-11 Impact factor: 10.793
Authors: Michelle L Hernandez; Margaret Herbst; John C Lay; Neil E Alexis; Willie June Brickey; Jenny P Y Ting; Haibo Zhou; David B Peden Journal: J Allergy Clin Immunol Date: 2012-07-04 Impact factor: 10.793
Authors: Neil E Alexis; Yuh Chin T Huang; Ana G Rappold; Howard Kehrl; Robert Devlin; David B Peden Journal: Am J Respir Crit Care Med Date: 2014-07-15 Impact factor: 21.405
Authors: Stavros Garantziotis; Zhuowei Li; Erin N Potts; Koji Kimata; Lisheng Zhuo; Daniel L Morgan; Rashmin C Savani; Paul W Noble; W Michael Foster; David A Schwartz; John W Hollingsworth Journal: J Biol Chem Date: 2016-09-09 Impact factor: 5.157
Authors: Benjamin W Frush; Zhuowei Li; Jane V Stiles; Sarah F Cotter; Scott L Shofer; W Michael Foster; John W Hollingsworth; Robert M Tighe Journal: J Allergy Clin Immunol Date: 2016-05-13 Impact factor: 10.793
Authors: Zhuowei Li; Robert M Tighe; Feifei Feng; Julie G Ledford; John W Hollingsworth Journal: J Biochem Mol Toxicol Date: 2012-11-20 Impact factor: 3.642
Authors: Allison J Burbank; Michelle L Hernandez; Carole Robinette; Ting Wang; Haibo Zhou; Neil Alexis; William D Bennett; David B Peden Journal: Inhal Toxicol Date: 2020-07-30 Impact factor: 2.724